Linked Life Data

20179216

Source:http://linkedlifedata.com/resource/pubmed/id/20179216

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2010-3-2
pubmed:abstractText
Characterization of new anticancer drugs in a few xenograft models derived from established human cancer cell lines frequently results in the discrepancy between preclinical and clinical results. To take the heterogeneity of tumors into consideration more thoroughly, we describe here a preclinical approach that may allow a more rational clinical development of new anticancer drugs.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
16
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1452-65
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer.
pubmed:affiliation
Bayer Schering Pharma AG, Global Drug Discovery, Berlin, Germany. stefanie.hammer@bayerhealthcare.com
pubmed:publicationType
Journal Article